Catheter ablation for persistent atrial fibrillation: does substrate modification improve outcomes

Persistent atrial fibrillation (AF) remains one of the more demanding rhythm disorders in contemporary electrophysiology. Episodes last longer, electrical remodelling becomes established, and structural changes in the atria can reduce the durability of rhythm control. Catheter ablation can restore sinus rhythm, yet the best strategy after pulmonary vein isolation (PVI) remains unsettled.

The central debate is whether treating additional atrial abnormalities—often described as substrate modification—improves outcomes beyond durable isolation of the pulmonary veins. These targets may include complex fractionated electrograms, low-voltage areas, linear conduction barriers, the posterior wall, autonomic sites, or organised rotational activity. Each approach has a plausible mechanistic basis, but biological plausibility has not always translated into better clinical trial results.

For clinicians across Australia, the question has practical significance. Access to advanced mapping, general anaesthesia, cardiac imaging and prolonged rhythm monitoring varies between metropolitan centres such as Sydney, Melbourne and Brisbane and regional services. Patient selection, procedural efficiency and follow-up arrangements therefore matter as much as the choice of lesion set.

Why persistent atrial fibrillation is different

Paroxysmal AF is commonly initiated by pulmonary vein triggers, making PVI a logical and often effective treatment. Persistent AF involves a more complex interaction between triggers and a remodelled atrial substrate. Fibrosis, atrial enlargement, conduction slowing and inflammation can allow fibrillation to continue after the original triggers have been isolated.

The term “persistent” covers a broad clinical spectrum. A patient with a first episode lasting eight days is different from someone with continuous AF for 18 months, severe left atrial enlargement and extensive fibrosis. Duration, rhythm burden, ventricular function, valvular disease, obesity, sleep apnoea, alcohol intake and hypertension all influence the likelihood of maintaining sinus rhythm.

These differences make a uniform ablation strategy difficult to justify. A substrate-directed lesion set may be valuable for a carefully selected patient with demonstrable scar, while adding lesions empirically may increase procedure time, atrial tachycardia and the risk of harm without improving freedom from AF.

What substrate modification means in practice

Substrate modification describes ablation beyond the pulmonary veins, although definitions differ between studies and laboratories. Operators may create roof or mitral isthmus lines, isolate the left atrial posterior wall, target low-voltage regions, eliminate complex fractionated atrial electrograms or use mapping systems intended to identify drivers of AF.

The posterior wall is an attractive target because it shares embryological and electrophysiological features with the pulmonary veins. It can contain triggers and may sustain fibrillatory activity. Linear ablation aims to interrupt large re-entry circuits, but incomplete lines can create a pro-arrhythmic substrate for organised atrial tachycardia. Low-voltage guided ablation attempts to personalise treatment by addressing diseased tissue rather than applying the same lesions to every patient.

The challenge is that atrial electrophysiology changes during anaesthesia, pacing, drug administration and different rhythms. Voltage maps can vary with catheter contact and cycle length, while complex fractionated electrograms may be transient. A visually appealing map does not necessarily identify the tissue responsible for long-term AF maintenance.

What the clinical evidence shows

The STAR AF II trial strongly influenced practice by finding that, in patients with persistent AF undergoing PVI, adding complex fractionated electrogram ablation or linear lesions did not significantly improve freedom from recurrent AF. Both adjunctive strategies increased the extent of ablation, while additional atrial tachyarrhythmias remained a concern.

More recent studies have also produced mixed findings. CAPLA did not show a significant improvement in the primary outcome from empirical posterior wall isolation added to PVI for persistent AF, although procedural details, follow-up and patient characteristics influence how its results should be interpreted. Studies of low-voltage guided ablation and MRI-defined fibrosis have suggested possible benefit in selected populations, but findings have not been sufficiently consistent to support an indiscriminate approach.

These results do not prove that substrate modification never works. They indicate that broad empirical ablation has limited evidence as a default strategy. Benefits may emerge when additional lesions are guided by reproducible abnormalities, re-entrant atrial tachycardia, documented non-pulmonary vein triggers or a repeat procedure showing gaps and recovered conduction.

Selecting patients for a tailored approach

A useful assessment begins before the procedure. Transthoracic echocardiography provides information about left atrial size, ventricular function and valve disease. Cardiac CT or MRI can support anatomical planning, while delayed-enhancement MRI may offer insight into atrial fibrosis where local expertise and image quality permit. These tests complement rather than replace clinical judgement.

Risk-factor management is part of substrate treatment. Weight reduction, blood pressure control, diabetes care, sleep apnoea assessment and reduction of heavy alcohol intake can improve rhythm outcomes. Australian patients may encounter different pathways through the public hospital system, private electrophysiology practices and Medicare-supported consultations, so clinicians should make follow-up and adjunctive care realistic from the outset.

Access also shapes selection. A patient travelling from regional New South Wales or Western Australia may find repeated procedures and intensive monitoring difficult, whereas a metropolitan patient may have easier access to device interrogation and same-week review. Aboriginal and Torres Strait Islander patients can face additional barriers related to distance, continuity of care and culturally safe communication. These realities should inform shared decision-making rather than being treated as administrative details.

Balancing rhythm control with procedural risk

Every additional lesion carries potential costs. Longer procedures increase exposure to anaesthesia, vascular complications and fluid shifts. Linear lesions require confirmed bidirectional block; otherwise, they may facilitate macro-reentrant atrial tachycardia. Posterior wall work can raise concerns about oesophageal injury, and extensive left atrial ablation may impair atrial mechanical function.

Newer energy sources, including pulsed field ablation (PFA), may change the balance between procedural speed, tissue selectivity and lesion durability. PFA has attracted interest for pulmonary vein isolation and selected adjunctive applications, but long-term evidence in persistent AF and broad substrate modification continues to develop. Availability, operator experience, local governance and Therapeutic Goods Administration status are relevant to Australian practice and should be considered alongside trial data.

Clinical success should also be defined carefully. Freedom from any atrial arrhythmia is a demanding endpoint, particularly when monitoring is intermittent. Symptom relief, reduced AF burden, improved exercise tolerance, fewer hospital presentations and preservation of ventricular function may be meaningful outcomes even when brief episodes recur. Anticoagulation decisions remain tied to thromboembolic risk, not simply apparent rhythm success.

Monitoring outcomes after ablation

The post-procedure period can include transient inflammation and early arrhythmia recurrence. A blanking period is commonly used when reporting outcomes, although the duration and interpretation of that period have evolved. Early recurrence may predict later failure, but it does not always require immediate repeat ablation.

Monitoring intensity influences the apparent success rate. A 12-lead electrocardiogram at clinic visits can miss asymptomatic episodes, while Holter monitoring, extended patches, implantable loop recorders and implanted device data provide progressively more detailed information. The chosen method should match the clinical question, recurrence risk and patient capacity.

For Australian services, a coordinated pathway may include the electrophysiologist, general practitioner, cardiac nurse and anticoagulation or heart failure teams. Clear instructions about palpitations, syncope, chest pain and medication changes are particularly important when patients return to rural or remote communities after treatment in a capital city.

Where the field is heading

The future of substrate modification is likely to be selective, integrated and biologically informed rather than defined by a single universal lesion set. High-density mapping, improved contact-force assessment, imaging integration, artificial intelligence and better identification of non-pulmonary vein triggers may help distinguish clinically important substrate from incidental electrical abnormality.

Randomised trials should prioritise durable rhythm outcomes, AF burden, quality of life, repeat procedures, atrial tachycardia and complications. They should also report how patients were selected, how lesions were confirmed and how rhythm was monitored. Without those details, apparently conflicting studies can be difficult to compare.

For readers of the Journal of Arrhythmia, this remains a productive area for original research, practical reviews and regional data. Investigators studying procedural strategies, health-system access or outcomes in the Asia-Pacific population can consult the journal’s author guidelines before preparing a manuscript.

The current evidence supports PVI as the foundation of ablation for persistent AF, with additional substrate treatment reserved for clearly defined indications or carefully selected patients. A personalised strategy that combines risk-factor modification, high-quality lesion assessment and meaningful long-term monitoring is more defensible than routine escalation of ablation for every patient.

Clinicians and researchers can help advance the field by reporting transparent procedural methods, patient-centred endpoints and follow-up that reflects real-world care. Continued collaboration between Australian centres, regional hospitals and international electrophysiology groups will be essential to determine when substrate modification improves outcomes and when it simply adds complexity.